ヒトマイクロバイオーム市場- 世界の産業規模、シェア、動向、機会、予測、製品別、用途別、疾患別、技術別、タイプ別、地域別、競合市場別、2020～2030年

ヒトマイクロバイオームの世界市場規模は2024年に6億1,525万米ドル、2030年には15億2,405万米ドルに達すると予測、CAGRは16.28%。

世界のヒトマイクロバイオーム市場は、マイクロバイオームが人間の健康や疾病に与える影響に対する科学的認識の高まりと、製薬会社やバイオテクノロジー企業による投資の増加によって、大きな変貌を遂げつつあります。この市場は、人体に生息する数兆個の微生物からなるヒト微生物叢を活用または改変して医療成果を向上させることを目的とした診断薬、治療、ヘルスケアソリューションの開発を包含しています。

市場促進要因

がん治療への応用拡大

主要市場課題

マイクロバイオームの機能に関する科学的複雑性と限定的な理解

主要市場動向

個別化されたマイクロバイオーム治療へのシフト

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 ヒトマイクロバイオーム市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（プレバイオティクス、プロバイオティクス、医療食品、サプリメント、その他）
  • 用途別（治療、診断）
  • 疾患別（感染症、内分泌・代謝疾患、消化器疾患、がん、その他）
  • 技術別（ゲノミクス、プロテオミクス、メタボロミクス）
  • タイプ別（FMT、ペプチド、生バイオ医薬品、その他）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米のヒトマイクロバイオーム市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のヒトマイクロバイオーム市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋のヒトマイクロバイオーム市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のヒトマイクロバイオーム市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのヒトマイクロバイオーム市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 製品上市
• 合併と買収

第13章 世界のヒトマイクロバイオーム市場：SWOT分析

第14章 競合情勢

• Enterome Bioscience SA
• Yakult Honsha Co. Ltd.
• 4 D Pharma
• Evelo Biosciences
• Seres Therapeutics Inc.
• Vedanta Biosciences
• Second Genome Inc.
• Quantibiome
• RebIoTix Inc.
• Microbiome Therapeutics LLC

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Human Microbiome market was valued at USD 615.25 Million in 2024 and is expected to reach USD 1524.05 Million by 2030 with a CAGR of 16.28%. The Global Human Microbiome Market is experiencing a significant transformation, fueled by growing scientific recognition of the microbiome's impact on human health and disease, along with increasing investments from pharmaceutical and biotechnology firms. This market encompasses the development of diagnostics, therapeutics, and healthcare solutions aimed at leveraging or modifying the human microbiota comprising trillions of microorganisms that inhabit the human body for improved medical outcomes.

Key Market Drivers

Increased Application in Cancer Treatment

Research has demonstrated that the human microbiome plays a crucial role in modulating immune responses, which directly impacts the efficacy of immunotherapies and chemotherapy. Certain gut microbiota strains have been found to enhance the effectiveness of immune checkpoint inhibitors, leading to improved patient outcomes. Biotech firms and pharmaceutical companies are investing in microbiome-derived drugs that can be used as adjunct therapies to traditional cancer treatments. These therapies aim to reduce treatment-related toxicity, improve drug absorption, and enhance immune system resilience.

The surge in clinical trials exploring microbiome-based interventions for cancer treatment is accelerating market growth. Studies are investigating how gut microbiota composition influences cancer progression and response to therapy. Rajiv Gandhi Cancer Institute and Research Centre (RGCIRC) has established itself as a premier clinical trial site, earning recognition from leading global cancer research institutions and pharmaceutical companies. With a track record of participation in over 300 national and international clinical trials, the center plays a pivotal role in advancing oncology research and innovative cancer therapies across diverse cancer types. Leading biotech firms and research institutions are forming strategic partnerships to develop microbiome-based cancer solutions. Increased funding from government agencies and private investors is driving innovation in microbiome therapeutics.

The integration of microbiome profiling into precision oncology is enabling personalized treatment plans tailored to individual patients. AI-driven microbiome analysis is helping identify biomarkers that predict cancer treatment responses. Regulatory bodies are recognizing the potential of microbiome-based therapies, leading to faster approvals and standardization efforts. The market is witnessing expansion into emerging economies, where cancer prevalence is rising.

Key Market Challenges

Scientific Complexity and Limited Understanding of Microbiome Functions

One of the most fundamental challenges impeding market growth is the incomplete and complex understanding of the human microbiome's structure, function, and interactions with host physiology. Despite major research advancements, scientists still face difficulties in: Differentiating between beneficial, neutral, and harmful microbes, Understanding causal relationships between microbiome imbalances and specific diseases, Establishing universal biomarkers or reference ranges for "healthy" microbiota.

This scientific uncertainty limits the ability of researchers and companies to design effective, targeted, and reproducible microbiome-based therapies. Moreover, it complicates clinical trial design and makes it harder to validate efficacy, slowing product development and investor confidence.

Key Market Trends

Shift Toward Personalized Microbiome-Based Therapies

The most significant trends fueling market growth is the rapid evolution of personalized medicine powered by microbiome insights. As scientific understanding of the human microbiome deepens, it is becoming increasingly clear that microbial compositions vary significantly across individuals. This has led to a paradigm shift from generalized probiotic or therapeutic approaches toward personalized microbiome interventions, including: Tailored probiotics and synbiotics based on individual gut flora, Microbiome profiling and diagnostics to guide treatment decisions, Customized dietary recommendations to optimize gut health and disease prevention.

This trend aligns with the broader healthcare movement toward precision medicine, offering more effective, safer, and targeted interventions. As genomic sequencing and microbiome mapping technologies become more accessible and affordable, personalized microbiome-based therapies are poised to redefine patient care.

Key Market Players

• Enterome Bioscience SA
• Yakult Honsha Co. Ltd.
• 4 D Pharma
• Evelo Biosciences
• Seres Therapeutics Inc.
• Vedanta Biosciences
• Second Genome Inc.
• Quantibiome
• Rebiotix Inc.
• Microbiome Therapeutics LLC

Report Scope:

In this report, the Global Human Microbiome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Microbiome Market, By Product:

• Prebiotics
• Probiotics
• Medical Food
• Supplements
• Others

Human Microbiome Market, By Application:

• Therapeutic
• Diagnostic

Human Microbiome Market, By Disease:

• Infectious Disease
• Endocrine and Metabolic Disorders
• Gastrointestinal Diseases
• Cancer
• Others

Human Microbiome Market, By Technology:

• Genomics
• Proteomics
• Metabolomics

Human Microbiome Market, By Type:

• FMT
• Peptide
• Live Biotherapeutic Product
• Others

Human Microbiome Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Microbiome Market.

Available Customizations:

Global Human Microbiome market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Human Microbiome Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Prebiotics, Probiotics, Medical Food, Supplements, Others)
  • 5.2.2. By Application (Therapeutic, Diagnostic)
  • 5.2.3. By Disease (Infectious Disease, Endocrine and Metabolic Disorders, Gastrointestinal Diseases, Cancer, Others)
  • 5.2.4. By Technology (Genomics, Proteomics, Metabolomics)
  • 5.2.5. By Type (FMT, Peptide, Live Biotherapeutic Product, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Human Microbiome Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Disease
  • 6.2.4. By Technology
  • 6.2.5. By Type
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human Microbiome Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Disease
      • 6.3.1.2.4. By Technology
      • 6.3.1.2.5. By Type
  • 6.3.2. Canada Human Microbiome Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Disease
      • 6.3.2.2.4. By Technology
      • 6.3.2.2.5. By Type
  • 6.3.3. Mexico Human Microbiome Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Disease
      • 6.3.3.2.4. By Technology
      • 6.3.3.2.5. By Type

7. Europe Human Microbiome Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Disease
  • 7.2.4. By Technology
  • 7.2.5. By Type
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human Microbiome Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Disease
      • 7.3.1.2.4. By Technology
      • 7.3.1.2.5. By Type
  • 7.3.2. United Kingdom Human Microbiome Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Disease
      • 7.3.2.2.4. By Technology
      • 7.3.2.2.5. By Type
  • 7.3.3. Italy Human Microbiome Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Disease
      • 7.3.3.2.4. By Technology
      • 7.3.3.2.5. By Type
  • 7.3.4. France Human Microbiome Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Disease
      • 7.3.4.2.4. By Technology
      • 7.3.4.2.5. By Type
  • 7.3.5. Spain Human Microbiome Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Disease
      • 7.3.5.2.4. By Technology
      • 7.3.5.2.5. By Type

8. Asia-Pacific Human Microbiome Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Disease
  • 8.2.4. By Technology
  • 8.2.5. By Type
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Human Microbiome Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Disease
      • 8.3.1.2.4. By Technology
      • 8.3.1.2.5. By Type
  • 8.3.2. India Human Microbiome Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Disease
      • 8.3.2.2.4. By Technology
      • 8.3.2.2.5. By Type
  • 8.3.3. Japan Human Microbiome Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Disease
      • 8.3.3.2.4. By Technology
      • 8.3.3.2.5. By Type
  • 8.3.4. South Korea Human Microbiome Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Disease
      • 8.3.4.2.4. By Technology
      • 8.3.4.2.5. By Type
  • 8.3.5. Australia Human Microbiome Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Disease
      • 8.3.5.2.4. By Technology
      • 8.3.5.2.5. By Type

9. South America Human Microbiome Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Disease
  • 9.2.4. By Technology
  • 9.2.5. By Type
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Human Microbiome Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Disease
      • 9.3.1.2.4. By Technology
      • 9.3.1.2.5. By Type
  • 9.3.2. Argentina Human Microbiome Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Disease
      • 9.3.2.2.4. By Technology
      • 9.3.2.2.5. By Type
  • 9.3.3. Colombia Human Microbiome Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Disease
      • 9.3.3.2.4. By Technology
      • 9.3.3.2.5. By Type

10. Middle East and Africa Human Microbiome Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Disease
  • 10.2.4. By Technology
  • 10.2.5. By Type
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Human Microbiome Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Disease
      • 10.3.1.2.4. By Technology
      • 10.3.1.2.5. By Type
  • 10.3.2. Saudi Arabia Human Microbiome Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Disease
      • 10.3.2.2.4. By Technology
      • 10.3.2.2.5. By Type
  • 10.3.3. UAE Human Microbiome Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Disease
      • 10.3.3.2.4. By Technology
      • 10.3.3.2.5. By Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Human Microbiome Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Enterome Bioscience SA
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Yakult Honsha Co. Ltd.
• 14.3. 4 D Pharma
• 14.4. Evelo Biosciences
• 14.5. Seres Therapeutics Inc.
• 14.6. Vedanta Biosciences
• 14.7. Second Genome Inc.
• 14.8. Quantibiome
• 14.9. Rebiotix Inc.
• 14.10.Microbiome Therapeutics LLC

15. Strategic Recommendations

16. About Us & Disclaimer